Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: muddphudd who wrote (402)	9/17/1998 11:49:00 PM
From: Martin Spallone	Respond to of 586

Actually its a 100% guess - but I have a pretty decent track record. AHP has a stake in IMNX and I figure this could be a drop in the bucket for either of them - sure they may not have any interest in RA but who knows. I'm thinking acquisition - who agrees ? The Aries fund did not acquire this much stock because it is an attractive stock. The only way they will make money for their investors is if CYPB gets acquired. They can't possibly dump 20% and get out ahead - esp. on a $2.00 stock. Anyway, @ 150mm its a no brainer for IMNX or AHP to take this and market it themselves esp. if it complements their product line. If people think CYPB is going to the moon and Aries will get out then think again - it backs up the acquisition theory and they win anyway. My guess is that CYPB assuming approval will go for 5X expected sales. Who would let a 150mm company have an exclusive to a 2bill market ? A buyer is ready when everyone least expects. When CYPB hits CNBC - its time to get out.